42,461 Shares in Omnicell, Inc. (NASDAQ:OMCL) Acquired by Roubaix Capital LLC

Roubaix Capital LLC purchased a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 42,461 shares of the company's stock, valued at approximately $1,851,000. Roubaix Capital LLC owned approximately 0.09% of Omnicell as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in OMCL. Arizona State Retirement System lifted its stake in shares of Omnicell by 2.9% in the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company's stock valued at $348,000 after purchasing an additional 357 shares during the period. Texas Permanent School Fund Corp lifted its position in Omnicell by 1.2% during the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company's stock valued at $1,158,000 after buying an additional 479 shares during the period. Diversified Trust Co boosted its holdings in shares of Omnicell by 3.3% during the 2nd quarter. Diversified Trust Co now owns 15,364 shares of the company's stock valued at $416,000 after buying an additional 494 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock worth $55,000 after buying an additional 553 shares during the period. Finally, Louisiana State Employees Retirement System increased its stake in shares of Omnicell by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company's stock worth $625,000 after acquiring an additional 600 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Bank of America reissued a "neutral" rating and set a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a research note on Thursday. Benchmark reiterated a "buy" rating and set a $48.00 price objective on shares of Omnicell in a research note on Wednesday, October 9th. Craig Hallum increased their target price on Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a research note on Thursday. JPMorgan Chase & Co. lifted their price target on Omnicell from $26.00 to $37.00 and gave the stock a "neutral" rating in a research report on Friday, August 23rd. Finally, StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Saturday, October 19th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $49.14.

Omnicell Stock Performance

Shares of NASDAQ OMCL traded down $4.41 during trading on Thursday, reaching $48.64. 1,061,254 shares of the company traded hands, compared to its average volume of 527,409. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. The firm has a 50 day simple moving average of $43.14 and a 200-day simple moving average of $35.07. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74. The stock has a market capitalization of $2.24 billion, a PE ratio of -124.72, a P/E/G ratio of 43.55 and a beta of 0.83.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.37. The business had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm's revenue was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 EPS. Equities research analysts anticipate that Omnicell, Inc. will post 0.64 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.